QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-initiates-coverage-on-fulcrum-therapeutics-with-overweight-rating-announces-price-target-of-23

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating a...

 goldman-sachs-upgrades-fulcrum-therapeutics-to-buy-raises-price-target-to-15

Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and raises the price t...

 hc-wainwright--co-reiterates-buy-on-fulcrum-therapeutics-maintains-17-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...

 oppenheimer-maintains-outperform-on-fulcrum-therapeutics-lowers-price-target-to-14

Oppenheimer analyst Matthew Biegler maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and lowers the price targ...

 goldman-sachs-upgrades-fulcrum-therapeutics-to-buy-announces-15-price-target

Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and announces $15 pric...

 fulcrum-therapeutics-q1-2024-gaap-eps-043-beats-044-estimate

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...

Core News & Articles

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. c...

 fulcrum-therapeutics-announces-publication-of-results-from-phase-2b-clinical-trial-of-losmapimod-in-facioscapulohumeral-muscular-dystrophy-in-the-lancet-neurology

― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings info...

 rbc-capital-initiates-coverage-on-fulcrum-therapeutics-with-outperform-rating-announces-price-target-of-14

RBC Capital analyst Gregory Renza initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform rating and anno...

 why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

 box-reports-upbeat-earnings-joins-american-public-education-wave-life-sciences-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

 hc-wainwright--co-maintains-buy-on-fulcrum-therapeutics-raises-price-target-to-17

HC Wainwright & Co. analyst Andrew Fein maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price tar...

 piper-sandler-maintains-overweight-on-fulcrum-therapeutics-raises-price-target-to-15

Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price ta...

 fulcrum-therapeutics-q4-gaap-eps-040-beats-043-estimate-sales-87100k-beat-46000k-estimate-cash-balance-of-2362m-expected-to-provide-cash-runway-into-2026

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of ...